Clinical Trial

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

Study acronym: (MET-IH)
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-02-10; most recent amendment 2026-04-17.
Status change: Not Yet Recruiting → Recruiting 2025-03-18
Trial Details
NCT Number NCT06829238
Lead Sponsor University of Alabama at Birmingham
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Systemic Inflammation, Immune Dysregulation, Injection Drug Use, HIV
Enrollment 100 participants
Start Date 2025-04-07
Primary Completion 2028-11-30 (estimated)
Study Completion 2029-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-22